Vericel to Present at the UBS Virtual Global Healthcare Conference on Wednesday, May 20, 2020
May 13 2020 - 8:30AM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
for the sports medicine and severe burn care markets, today
announced that Nick Colangelo, president and CEO, will present the
latest company overview at the UBS Virtual Global Healthcare
Conference. The conference is being conducted with a virtual
format and the presentation will take place on Wednesday, May 20,
2020 at 12:30pm Eastern Time.
A live webcast of the presentation will be
available on the Investor Relations section of the Vericel
Corporation website at: http://investors.vcel.com
About Vericel
CorporationVericel is a leader in advanced therapies for
the sports medicine and severe burn care markets. The company
markets two cell therapy products in the United States. MACI®
(autologous cultured chondrocytes on porcine collagen membrane) is
an autologous cellularized scaffold product indicated for the
repair of symptomatic, single or multiple full-thickness cartilage
defects of the knee with or without bone involvement in
adults. Epicel® (cultured epidermal autografts) is a
permanent skin replacement for the treatment of patients with deep
dermal or full thickness burns greater than or equal to 30% of
total body surface area. The company also holds an exclusive
license for North American commercial rights to NexoBrid®, a
registration-stage biological orphan product for debridement of
severe thermal burns. For more information, please visit the
company's website at www.vcel.com.
Epicel® and MACI® are registered trademarks of
Vericel Corporation. NexoBrid® is a registered trademark of
MediWound Ltd. and is used under license to Vericel
Corporation. © 2019 Vericel Corporation. All rights
reserved.
Investor Contacts:Lee
SternSolebury Troutlstern@troutgroup.com+1 646-378-2922
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Apr 2023 to Apr 2024